Latvija - latviešu - Zāļu valsts aģentūra

sandoz d.d., slovenia - piperacillinum, tazobactamum - pulveris infūziju šķīduma pagatavošanai - 4000 mg/500 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatas audzēji - citi hormonu antagonisti un tiem līdzīgas vielas - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Latvija - latviešu - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - zolpidēma tartrāts - apvalkotā tablete - 10 mg

Latvija - latviešu - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - zolpidēma tartrāts - apvalkotā tablete - 5 mg

Latvija - latviešu - Zāļu valsts aģentūra

vip pharma eesti ou, estonia - skābes acetylsalicylicum, paracetamolum, kofeīns - tablete

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Latvija - latviešu - Zāļu valsts aģentūra

mip pharma gmbh, germany - klindamicīns - Šķīdums injekcijām/infūzijām - 900 mg/6 ml

Latvija - latviešu - Zāļu valsts aģentūra

mip pharma gmbh, germany - klindamicīns - Šķīdums injekcijām/infūzijām - 600 mg/4 ml

Latvija - latviešu - Zāļu valsts aģentūra

glaxosmithkline trading services limited, ireland - paroksetīns - apvalkotā tablete - 20 mg